Skip to main content
. 2020 Mar 2;12(4):e11177. doi: 10.15252/emmm.201911177

Figure 5. RSK‐EphA2‐pS897 inhibition enhances EphA2‐pY588 and sensitizes OC cells to platinum chemotherapy.

Figure 5

  • A, B
    Charts show OC cell viability after 72‐h treatment with 0–20 μM cisplatin and 10 μM BI‐D1870 (A; N = 4) or with 50 μM LJH685 (B; N = 3) as indicated.
  • C
    RSK and EphA2 (total and phosphorylated) in OC cells treated with 10 µM cisplatin and 25 µM LJH685 as indicated for 72 h.
  • D
    Charts illustrate the corresponding quantified inhibition of EphA2‐pS897 and increase in EphA2‐pY588 shown in (C).
Data information: In (A, B), data are presented as mean (SD). *P < 0.05, **P < 0.01, ***P < 0.001. Exact P‐values are provided in Appendix Table S10, Student's t‐test.Source data are available online for this figure.